People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | — | Biotechnology | Series D+ | $569.0M | $2.4B | 2024 |
| Pulse Biosciences, Inc. | — | Biotechnology | Series C | $93.0M | $1.4B | 2021 |
| Kallyope, Inc. | — | Biotechnology | Series B | $28.1M | $1.1B | 2015 |
Kenneth Clark at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kenneth Clark on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Duggan | 2 | 3 |
| Mahkam Zanganeh | 2 | 3 |
| Manmeet Soni | 2 | 2 |
| Jeff Huber | 1 | 75 |
| Michael O'Donnell | 1 | 11 |
| Adam Goulburn | 1 | 10 |
| Terry McGuire | 1 | 8 |
| Mostafa Ronaghi | 1 | 8 |
| Tim Kutzkey | 1 | 7 |
| David Wurzer | 1 | 7 |
| Amy Wang | 1 | 5 |
| Robert Booth | 1 | 4 |
| Joshua Wolfe | 1 | 4 |
| Jim Mellon | 1 | 4 |
| William Rieflin | 1 | 4 |
| Darrin Uecker | 1 | 3 |
| Raymond Spencer | 1 | 3 |
| David Roblin | 1 | 3 |
| Christopher Marlett | 1 | 3 |
| Leopoldo Zambeletti | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.